Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos, P

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. [electronic resource] - Cancer chemotherapy and pharmacology Feb 2012 - 533-46 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1432-0843

10.1007/s00280-011-1730-9 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Breast Neoplasms--drug therapy
Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
Cluster Analysis
Disease-Free Survival
Dose-Response Relationship, Drug
Estrogen Receptor alpha--genetics
Estrogen Receptor beta--genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Middle Aged
Outcome Assessment, Health Care--methods
Phenotype
Prognosis
Randomized Controlled Trials as Topic
Receptor, ErbB-2--genetics
Receptors, Estrogen--genetics
Receptors, Progesterone--genetics
Reverse Transcriptase Polymerase Chain Reaction
Translational Research, Biomedical--methods
Young Adult